Pharmacodynamic Biomarkers | Pharmacological Effects | Parallel Reaction Monitoring

Services

Pharmacodynamic Biomarkers

Customized multiplexed investigation of biomarkers and downstream drug-induced effects

Pharmacodynamic (PD) studies are fundamental to determining the efficacy and safety of therapeutic agents. Detecting and validating effective biomarkers speeds up decision-making in early drug development and supports clinical trial advancement. Our Pharmacodynamic Biomarkers solution enables accurate and highly sensitive absolute quantification of PD biomarkers to ensure the success of your drug development project.

    By selecting any or all of the topic preferences below, you agree to receive respective information from Biognosys via email. You can unsubscribe from these communications at any time. By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

      By selecting any or all of the topic preferences below, you agree to receive respective information from Biognosys via email. You can unsubscribe from these communications at any time. By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

      Description

      The inability to demonstrate efficacy or presence of safety concerns are among the primary reasons why clinical trials fail¹.

      Reliable PD biomarkers allow early decision-making to provide critical information about the selection of lead compounds, target effect, biological response, effects of the combination of targeted agents, target engagement in vivo, and how to optimize schedules of a drug regime.

      Our TrueSignature® pharmacodynamic biomarker panels are powered by Parallel Reaction Monitoring (PRM) and SureQuant mass spectrometry. These technologies allow for complete customization down to amino acid resolution (i.e. mutations, truncations, isoforms) and are not dependent on affinity-based recognition and reagent availability. You select the proteins; we analyze them for you.

      Our TrueSignature platform offers industry-leading customization, with versatile protein combination options, encompassing single proteins, multiplex panels of up to 50 proteins, and even hyperplex panels of up to 800 proteins. The panels can be developed within weeks and are available both as a standalone solution or as an integrated solution, in which insights from TrueDiscovery® studies help guide the selection of peptides in the custom panel.

      Resources

      Filter By

      Deliverables

      The results are presented and discussed with you in a dedicated conference call and delivered electronically in PDF and Excel format.

      Executive Summary
      Materials and Methods
      (suitable for publication)
      Complete Data Matrix

      a) Peptide and protein relative intensities for all study samples
      b)       Peptide and protein absolute quantities based on stable isotope standards (if applicable)

      Data Interpretation

      a) Differentially regulated proteins with regulation factor and p-value
      b) Coefficient of variation analysis
      c) Multivariate analysis (e.g., PCA)
      d) Hierarchical clustering analysis
      e) Custom analysis upon request

      Sample types and depths

      Our Pharmacodynamic Biomarkers solution can be applied to virtually any sample type and species with minimal sample input.

      SAMPLE REQUIREMENTS

      Project management

      Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.

      WORKING WITH US

       

      Contact